{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:54:39Z","timestamp":1793501679499,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term outcome on breast cancer surveillance in BRCA mutation carriers are limited, especially in Asian populations where uptake of preventive surgery is low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of 722 female\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutation carriers enrolled between January 2007 and December 2024 in the Hong Kong Hereditary Breast Cancer Family Registry. Of these, 702 (97.2%) underwent structured high-risk surveillance comprising biannual clinical breast examination and alternating 6-monthly breast magnetic resonance imaging and mammography or digital breast tomosynthesis with ultrasonography. The outcomes were breast cancer detection rate, stage, nodal status, interval cancer occurrence, and breast cancer\u2013specific mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Risk-reducing mastectomy was undertaken by 90 out of 722 carriers (12.5%). Surveillance detected 64 breast cancers during 4,398 imaging sessions (detection rate 1.5%). Most cancers (89.1%) were diagnosed at stage 0 or I, and 95.3% were node- negative. Interval cancers were uncommon. Among 304 carriers initially free of breast cancer who later developed the disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926), no breast cancer\u2013specific death occurred. Overall, breast cancer\u2013specific mortality in the cohort was 2.4%, with most deaths due to ovarian cancer with a median follow-up of 39.1 months (range, 6-212.3). Longer term follow-up is warranted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this first Asian surveillance cohort of BRCA mutation carriers, prophylactic mastectomy uptake was low, yet structured screening enabled early-stage detection and minimal interval cancer. Surveillance should be considered as a key management strategy, with preventive surgery options individualized and cost-effectiveness evaluated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01822-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:56:54Z","timestamp":1770127014000},"page":"407-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers"],"prefix":"10.1007","volume":"33","author":[{"given":"Yuk-Kwan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Pan","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hiu","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-9489","authenticated-orcid":false,"given":"Ava","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"5","key":"1822_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Luccarini C, Wahlstr\u00f6m C, et al. Breast cancer risk Genes - Association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428\u201339.","journal-title":"N Engl J Med"},{"key":"1822_CR2","doi-asserted-by":"crossref","unstructured":"Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94(18):1358\u201365.","DOI":"10.1093\/jnci\/94.18.1358"},{"issue":"15","key":"1822_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Cancer risks","year":"1999","unstructured":"Cancer risks. BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"1822_CR4","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887\u201392.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1822_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-021-06446-7","volume":"192","author":"PH Lin","year":"2022","unstructured":"Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC, et al. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Res Treat. 2022;192(3):629\u201337.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1822_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","volume":"125","author":"VR Grann","year":"2011","unstructured":"Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, et al. Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125(3):837\u201347.","journal-title":"Breast Cancer Res Treat"},{"key":"1822_CR7","doi-asserted-by":"crossref","unstructured":"Liu T, Yu J, Gao Y, Ma X, Jiang S, Gu Y et al. Prophylactic interventions for hereditary breast and ovarian cancer risks and mortality in BRCA1\/2 carriers. Cancers (Basel). 2023;16(1):103.","DOI":"10.3390\/cancers16010103"},{"issue":"4","key":"1822_CR8","first-page":"CD002748","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1822_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41416-023-02503-8","volume":"130","author":"K Metcalfe","year":"2024","unstructured":"Metcalfe K, Huzarski T, Gronwald J, Kotsopoulos J, Kim R, Moller P, et al. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. Br J Cancer. 2024;130(2):269\u201374.","journal-title":"Br J Cancer"},{"key":"1822_CR10","doi-asserted-by":"crossref","unstructured":"Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 2025;26(6):759\u201370.","DOI":"10.1016\/S1470-2045(25)00152-4"},{"issue":"3","key":"1822_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","volume":"177","author":"BAM Heemskerk-Gerritsen","year":"2019","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AIM, Coll\u00e9e M, Meijers-Heijboer HEJ, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723\u201333.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1822_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.amjsurg.2018.02.010","volume":"215","author":"R Morgan","year":"2018","unstructured":"Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K. Risk management decisions in women with BRCA1 and BRCA2 mutations. Am J Surg. 2018;215(5):899\u2013903.","journal-title":"Am J Surg"},{"issue":"4","key":"1822_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","volume":"77","author":"AB Skytte","year":"2010","unstructured":"Skytte AB, Gerdes AM, Andersen MK, Sunde L, Br\u00f8ndum-Nielsen K, Waldstr\u00f8m M, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77(4):342\u20139.","journal-title":"Clin Genet"},{"key":"1822_CR14","doi-asserted-by":"crossref","unstructured":"Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15\u201321.","DOI":"10.1038\/s41416-019-0446-1"},{"issue":"2","key":"1822_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1822_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jnci\/djy182","volume":"111","author":"MB Terry","year":"2019","unstructured":"Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, et al. Risk-Reducing oophorectomy and breast cancer risk across the spectrum of Familial risk. J Natl Cancer Inst. 2019;111(3):331\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1822_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1200\/JCO.2001.19.4.924","volume":"19","author":"CT Brekelmans","year":"2001","unstructured":"Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. Effectiveness of breast cancer surveillance in BRCA1\/2 gene mutation carriers and women with high Familial risk. J Clin Oncol. 2001;19(4):924\u201330.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1822_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1148\/radiology.209.2.9807581","volume":"209","author":"RD Rosenberg","year":"1998","unstructured":"Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kelsey CA, et al. Effects of age, breast density, ethnicity, and Estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, new Mexico. Radiology. 1998;209(2):511\u20138.","journal-title":"Radiology"},{"issue":"2","key":"1822_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/RLI.0b013e3181f3fcdf","volume":"46","author":"F Sardanelli","year":"2011","unstructured":"Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): final results. Invest Radiol. 2011;46(2):94\u2013105.","journal-title":"Invest Radiol"},{"key":"1822_CR20","doi-asserted-by":"crossref","unstructured":"Houssami N, Macaskill P, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al. Breast screening using 2D-mammography or integrating digital breast tomosynthesis (3D-mammography) for single-reading or double-reading\u2013evidence to guide future screening strategies. Eur J Cancer. 2014;50(10):1799\u2013807.","DOI":"10.1016\/j.ejca.2014.03.017"},{"issue":"1","key":"1822_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mric.2009.09.005","volume":"18","author":"EA Morris","year":"2010","unstructured":"Morris EA. Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am. 2010;18(1):57\u201374.","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"9","key":"1822_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.7326\/0003-4819-148-9-200805060-00007","volume":"148","author":"E Warner","year":"2008","unstructured":"Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 2008;148(9):671\u20139.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1822_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2023.6944","volume":"10","author":"J Lubinski","year":"2024","unstructured":"Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024;10(4):493\u20139.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1822_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/Familial High-Risk assessment: Breast, Ovarian, and Pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(1):77\u2013102.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1822_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023;34(1):33\u201347.","journal-title":"Ann Oncol"},{"key":"1822_CR26","doi-asserted-by":"crossref","unstructured":"Kwong A. Genetic testing for hereditary breast cancer in Asia-moving forward. Chin Clin Oncol. 2016;5(3):47.","DOI":"10.21037\/cco.2016.05.11"},{"issue":"1","key":"1822_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41598-018-19437-4","volume":"8","author":"LY Lim","year":"2018","unstructured":"Lim LY, Ho PJ, Liu J, Chay WY, Tan MH, Hartman M, et al. Determinants of breast size in Asian women. Sci Rep. 2018;8(1):1201.","journal-title":"Sci Rep"},{"issue":"5","key":"1822_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/ije\/30.5.959","volume":"30","author":"G Maskarinec","year":"2001","unstructured":"Maskarinec G, Meng L, Ursin G. Ethnic differences in mammographic densities. Int J Epidemiol. 2001;30(5):959\u201365.","journal-title":"Int J Epidemiol"},{"issue":"Suppl 2","key":"1822_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ajco.13116","volume":"15","author":"A Kwong","year":"2019","unstructured":"Kwong A, Cheng KLD, Hsue CCV, Hui SK, Leung CYR, Leung KCA, et al. BRCA mutation testing for ovarian cancer in the context of available targeted therapy: survey and consensus of Hong Kong specialists. Asia Pac J Clin Oncol. 2019;15(Suppl 2):20\u201331.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"1822_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.breast.2013.10.008","volume":"23","author":"Y Sim","year":"2014","unstructured":"Sim Y, Tan VKM, Ho GH, Wong CY, Madhukumar P, Tan BKT, et al. Contralateral prophylactic mastectomy in an Asian population: a single institution review. Breast. 2014;23(1):56\u201362.","journal-title":"Breast"},{"issue":"4","key":"1822_CR31","doi-asserted-by":"publisher","first-page":"e695","DOI":"10.1016\/j.clbc.2017.12.005","volume":"18","author":"Y Laitman","year":"2018","unstructured":"Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, et al. Abnormal findings detected by Multi-modality breast imaging and biopsy results in a High-risk clinic. Clin Breast Cancer. 2018;18(4):e695\u20138.","journal-title":"Clin Breast Cancer"},{"key":"1822_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.breast.2019.10.012","volume":"49","author":"R Bernstein-Molho","year":"2020","unstructured":"Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, et al. Breast cancer surveillance for BRCA1\/2 mutation carriers - is early detection early enough? Breast. 2020;49:81\u20136.","journal-title":"Breast"},{"key":"1822_CR33","doi-asserted-by":"crossref","unstructured":"Kostov AM, Jensen MB, Ejlertsen B, Thomassen M, Rossing M, Pedersen IS, et al. Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study. Breast Cancer Res Treat. 2025;212(2):309\u201323.","DOI":"10.1007\/s10549-025-07726-2"},{"issue":"10","key":"1822_CR34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1177\/0003134820964208","volume":"86","author":"A Fong","year":"2020","unstructured":"Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, et al. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Am Surg. 2020;86(10):1243\u20137.","journal-title":"Am Surg"},{"issue":"12","key":"1822_CR35","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamasurg.2014.1081","volume":"149","author":"A Gangi","year":"2014","unstructured":"Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, et al. Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg. 2014;149(12):1306\u201313.","journal-title":"JAMA Surg"},{"issue":"1","key":"1822_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ygyno.2021.10.077","volume":"164","author":"CS John","year":"2022","unstructured":"John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, et al. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Gynecol Oncol. 2022;164(1):202\u20137.","journal-title":"Gynecol Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01822-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:02:57Z","timestamp":1781650977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01822-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01822-x","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}